ASH 2023 | Siltuximab for the management of CAR-T toxicities: a multicenter retrospective study
In this video, Timothy Voorhees, MD, MSCR, The Ohio State University Wexner Medical Center, Columbus, OH, briefly comments on the findings of a multicenter retrospective analysis assessing the efficacy of siltuximab in managing CAR T-cell therapy-related toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Response rates to this agent were high, especially in patients refractory to tocilizumab. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So this was another retrospective study that we looked at the use of siltuximab for managing cytokine release syndrome and immune-effector cell neurotoxicity syndrome. And so what we found was a combination of patients, again, retrospective multicenter study, where some patients were treated in the frontline with siltuximab due to the tocilizumab shortage in the past, and other patients were treated in the tocilizumab refractory setting with siltuximab...
So this was another retrospective study that we looked at the use of siltuximab for managing cytokine release syndrome and immune-effector cell neurotoxicity syndrome. And so what we found was a combination of patients, again, retrospective multicenter study, where some patients were treated in the frontline with siltuximab due to the tocilizumab shortage in the past, and other patients were treated in the tocilizumab refractory setting with siltuximab. The response rates with siltuximab for both neurotoxicity and for cytokine release syndrome were high, and specifically in the patients that were refractory to tocilizumab, about 50% of those patients responded to siltuximab treatment.
Read more...
Disclosures
Consultancy: Novartis, Recordati; Research Funding: Recordati, AstraZeneca, Incyte, Morphosys.
